We are thrilled to partner with Reunion Neuroscience in their groundbreaking study on RE104 for postpartum depression," said Dr. Elizabeth Nielson, Co-founder and Chief Visionary Officer at Fluence. "By leveraging our expertise in psychedelic therapy training within the clinical research environment, we aim to support Reunion Neuroscience in conducting a rigorous and successful clinical trial, ultimately contributing to the advancement of this innovative treatment for postpartum depression.